Renovorx ceo issues letter to shareholders

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from chief executive officer, shaun bagai. dear fellow renovorx shareholders, 2023 was a pivotal year for renovorx, and we believe our accomplishments bode well for the achievement of our anticipated 2024 milestones. our team worked.
RNXT Ratings Summary
RNXT Quant Ranking